Glenmark Pharma gets final USFDA nod for migraine drug
Posted on:16 Mar 2016 15:07:18
Free Current Affairs to Your Email
16 March 2016 Current Affairs: GlenmarkBSE 1.46 % Pharma has received final nod from the USFDA to manufacture and market therapeutical equivalent of Endo Pharmaceutical's Frova tablets, used to treat migraine headaches, in the US market. Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (USFDA) for Frovatriptan Succinate Tablets, 2.5 mg.the drug is "therapeutical equivalent of Endo Pharmaceutical's Frova tablets 2.5 mg." Quoting IMS data, Glenmark said the approved product has an estimated market size of $87.8 million for the 12 months ended January 2016. The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US. Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.It manufactures and markets generic formulation products and active pharmaceutical ingredients, both in the domestic and international markets.The company's current portfolio consists of 61 ANDAs pending approvals from the USFDA and 108 products authorised for distribution in the US.
FreshersLive - No.1 Job site in India. Here you can find latest 2017 government as well as private job recruitment notifications for different posts vacancies in India. Get top company jobs for both fresher and experienced. Job Seekers can get useful interview tips, resume services & interview Question and answer. Practice online test free which is helpful for interview preparation. Register with us to get latest employment news/rojgar samachar notifications. Also get latest free govt and other sarkari naukri job alerts daily through E-mail.